Company Encyclopedia
View More
name
ALX Oncology
ALXO.US
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Symposium; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc.
1.946 T
ALXO.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    ALX Oncology Holdings Inc. to Present at Piper Sandler Healthcare Conference

    ALX Oncology Holdings Inc. will present at the Jefferies Global Healthcare Conference in London on November 19, 2025, and the Piper Sandler 37th Annual Global Healthcare Conference in New York on December 3, 2025. The company will share updates on its cancer therapies pipeline through fireside chats, with webcasts available on its website. This information is AI-generated and not financial advice.

    Reuters·
    US
    ALXO
    +3.79%
    Reuters·
    US
    ALXO
    +3.79%

    ALX Oncology Holdings (ALXO) Gets a Buy from Jefferies

    Jefferies analyst initiated coverage with a Buy rating on ALX Oncology Holdings, setting a price target of $4.00. H.C. Wainwright also issued a Buy rating, while LifeSci Capital maintained a Hold rating. The news highlights differing analyst opinions on ALX Oncology Holdings.

    Tip Ranks·
    US
    ALXO
    +3.79%
    Tip Ranks·
    US
    ALXO
    +3.79%

    Alx Oncology Earnings Call: Optimism Amid Challenges

    Alx Oncology Holdings, Inc. held its Q3 earnings call, showcasing optimism due to strong clinical results for its lead drugs, evorpacept and ALX2004. Evorpacept demonstrated a 65% objective response rate in trials for HER2-positive gastric cancer. The company has a solid cash position of $67 million, supporting operations until 2027. Despite challenges in market positioning and historical toxicity concerns with ADCs, Alx is advancing its clinical programs, including a Phase II breast cancer trial and ALX2004's Phase I trials. The outlook remains positive as the company navigates these challenges.

    Tip Ranks·
    US
    ALXO
    +3.79%
    Tip Ranks·
    US
    ALXO
    +3.79%

    ALX Oncology Reports Promising Q3 2025 Results

    ALX Oncology Holdings, Inc. (ALXO) reported its Q3 2025 earnings, showcasing significant advancements in clinical trials, especially for its lead candidate, evorpacept, in HER2-positive gastric cancer. The company initiated a Phase 2 trial for breast cancer and ongoing Phase 1 trials for ALX2004. Financially, ALX Oncology noted a reduction in research and development expenses and net loss, with a cash runway extending into Q1 2027. The company remains optimistic about its clinical programs and aims to achieve key milestones in the future.

    Tip Ranks·
    US
    ALXO
    +3.79%
    Tip Ranks·
    US
    ALXO
    +3.79%

    ALX Oncology | 10-Q: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    ALXO
    +3.79%
    LB filings·
    US
    ALXO
    +3.79%
    © 2025 Longbridge｜Disclaimer